Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SHR0302 Alkali Gel in Healthy Subjects
NCT07098117Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ivarmacitinib in atopic dermatitis (AD), alopecia areata and Vitiligo (4 arms), sponsored by Hengrui. Primary endpoints: Skin local tolerability (moderate and above incidence) at 8 days and Adverse events at 8 days. Started Jun 2024; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
atopic dermatitis (AD)alopecia areataVitiligo
Beyond the preview
Go deeper on NCT07098117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098117.